Sinefungin is a potent inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2-)-methyltransferase, and viral multiplication. Sinefungin, a SET7/9 inhibitor, ameliorates renal fibrosis by inhibiting H3K4 methylation.
性状
Solid
体外研究(In Vitro)
Sinefungin (0.5 or 1.0 μg/mL, 60 minutes) ameliorates the TGF-β1-induced increase of α-SMA and inhibits the upregulation of histone H3K4 monomethylation in renal epithelial cells and renal fibroblast cells.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis
Cell Line:
Renal epithelial cells.
Concentration:
0.5 or 1.0 μg/mL.
Incubation Time:
Pretreatment 60 minutes before TGF-β1 (10 ng/mL).
Result:
Significantly reduced TGF-β1-inducedα-SMA protein expression and inhibited H3K4me1 in a dose-dependent manner in both NRK-52E and NRK-49F cells.
体内研究(In Vivo)
Sinefungin (10 mg/kg, per day immediately after UUO) ameliorates renal fibrosis in obstructive nephropathy.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Male C57BL/6J mice (8 weeks of age).
Dosage:
10 mg/kg
Administration:
Administered intraperitoneally per day immediately after UUO (prepared as a suspension in distilled water and 0.9% NaCl solution).
Result:
Inhibited α-SMA protein expression.
Ameliorated those (α-SMA, FSP-1, collagen 1, collagen 3) both at 3 and 7 days after UUO.